Back

VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

iwNHL 2015 | Approaches to overcome side effects of idelalisib for follicular lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, John Gribben, MD, DSc, FRCPath, FRCP FMedSci, of Barts and The London School of Medicine and Dentistry, London, UK, discusses the efficacy and safety of idelalisib, a first-in-class selective oral inhibitor of phosphoinositide 3-kinase (PI3K) delta, for the treatment of patients with follicular lymphoma.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter